HAGAR Shares New Clinical Data on GWave Technology

HAGAR is releasing data from a proprietary study conducted at the Weizmann Institute of Science on the GWave device that demonstrate the accuracy and scalability of the firm’s GWave technology product for the wellness and diabetic space.

HAGAR also has closed $5 million in Round C funding, bringing its total raised to date to $25 million. 
  
Professor Ami Navon of the Weizmann Institute of Science led a study of 75 diverse individuals in age, gender, and race: Thirty-four with diabetes (82% Type I diabetes), 10 pregnant women with diabetes, and 31 without diabetes. Non-invasive monitoring was performed on the wrist, and comparators included BGM and two commercial CGMs. A noteworthy aspect of the study involved participants undergoing a glucose challenge, which showcased the accuracy and consistency of the GWave device in tracking fluctuating blood glucose trends. GWave performed with a 6.7% mean MARD; 97% of points fell in Zone A and 3% fell in Zone B of the Clarke Error Grid, with blood glucose levels.
 
In addition, HAGAR ran a hypoglycemic test with Dr. Irl Hirsch and his brother James Hirsch, a well-known former New York Times and Wall Street Journal reporter and best-selling author of “Living With Diabetes.” In an impressive outcome, Dr. Hirsch lowered his glucose levels from 180 to 46 while GWave accurately monitored his blood glucose levels.
 
This clinical study and test results form part of HAGAR’s ongoing pursuit to showcase its technology’s increased accuracy and efficacy in an effort to bring the device to market. In its final form, the GWave technology will be ready for integration into a smartwatch at a low-level cost, making it even more accessible and affordable for patients globally. The accuracy of such a device opens the door to those outside of the diabetes community through health optimization and the potential to prevent chronic illness.
 
These achievements follow the company’s pathway to market with its Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) in 2021. Additional studies are planned centered on the full blood glucose range in the United States with Dr. Roy Beck, founder of the Jaeb Center for Health Research, and in Israel.

GWave non-invasively and accurately monitors blood glucose levels in real time. The device’s seamless integration with Bluetooth and smartphone technology allow users to track their glucose readings on demand. The GWave device’s automated alert system is designed to inform users of any significant glucose level fluctuations. This device monitors blood glucose in the blood itself, not in the interstitial fluid, resulting in great precision, according to the company.
 
HAGAR N.I.G. (Noninvasive Glucose monitoring) is the developer of GWave, the world’s first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood continuously. GWave First Generation is a third of the size of a smartphone, and GWave Second Generation, currently in development, will be a sensor built into a comfortable watch the size of a smartwatch that sends glucose readings to the user via a smartphone app that can easily be shared with their healthcare provider.